Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Verdiva Bio
Biotech
Verdiva axes GLP-1 switching trial over ‘market evolution’
Verdiva Bio has scrapped a phase 2 trial of its once-weekly oral GLP-1 drug candidate, pulling the plug the year after launching with $410 million.
Nick Paul Taylor
Oct 14, 2026 10:13am
Biogen R&D vet gets in Formation—Chutes & Ladders
Jul 24, 2026 8:30am
Biotech's top money raisers: 2025
Mar 2, 2026 6:30am
Verdiva launches with $410M, weekly-dosed oral GLP-1 candidate
Jan 9, 2025 2:00am
